# Why AI Will Accelerate Drug Discovery, Not Replace Biotech Teams

Page: https://stenobird.com/podcast/the-tech-leader-s-playbook-6409231/why-ai-will-accelerate-drug-discovery-not-replace-biotech-teams
Text version: https://stenobird.com/podcast/the-tech-leader-s-playbook-6409231/why-ai-will-accelerate-drug-discovery-not-replace-biotech-teams.md
Podcast: [The Tech Leader's Playbook](https://stenobird.com/podcast/the-tech-leader-s-playbook-6409231)
Published: 2026-03-11T20:30:01+00:00
Episode link: https://podcasters.spotify.com/pod/show/thetechleaderplaybook/episodes/Why-AI-Will-Accelerate-Drug-Discovery--Not-Replace-Biotech-Teams-e3ga63t
Audio file: https://anchor.fm/s/e2d189bc/podcast/play/116774461/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-2-11%2F419814510-44100-2-8c44031479258.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-tech-leader-s-playbook-6409231/episodes/why-ai-will-accelerate-drug-discovery-not-replace-biotech-teams
Duration seconds: 3028

## Resource

For more thoughts, clips, and updates, follow Avetis Antaplyan on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/avetisantaplyan⁠⁠⁠⁠ In this episode of The Tech Leader's Playbook, Avetis Antaplyan sits down with Alok Tayi, a Harvard-trained scientist, repeat tech founder, and the founder of Vibe Bio. Alok shares his journey from academia and engineering into entrepreneurship, where he built multiple pharmaceutical software companies collectively worth nearly $1 billion before launching Vibe Bio with a deeply personal mission. After his daughter was born with two rare diseases that had no available treatments, Alok turned his attention to one of biotech’s most overlooked challenges: accelerating innovation for rare disease patients. The conversation explores how AI is changing drug discovery, why rare disease innovation has historically been underfunded, and how new tools, data, and regulatory pathways are creating fresh opportunities for founders and investors alike. Alok explains how Vibe Bio uses proprietary AI to evaluate drug programs, support pharma decision-making, and guide venture investments into high-potential therapeutics. He also shares hard-won lessons on leadership, mission-driven company building, culture, and the importance of staying obsessed with the problem while remaining flexible on tactics. This episode is a thoughtful look at the intersection of science, entrepreneurship, capital, and meaningful impact. Takeaways Intro to Alok Tayi and the mission behind Vibe Bio From scientist to serial founder in life sciences software How Alok’s daughter’s diagnosis changed his life and career Leadership lessons from scaling companies at different stages What Vibe Bio actually does and how its AI works Why biotech and pharma are harder than most founders expect Bal…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-tech-leader-s-playbook-6409231/episodes/why-ai-will-accelerate-drug-discovery-not-replace-biotech-teams/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-tech-leader-s-playbook-6409231/why-ai-will-accelerate-drug-discovery-not-replace-biotech-teams.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.